Abstract
Budipine (Hackmack et al. 1979) has been proven as an effective drug in experiments in animals (Menge and Brand 1982) as well as in clinical investigations for treating patients (Siegfried 1982) suffering from parkinsonian syndrome. The present report includes a summary of the studies hitherto conducted on the pharmacokinetics and metabolism of budipine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dost FH (1968) Grundlagen der Pharmakokinetik. Thieme, Stuttgart
Hackmack G, Menge HG, Eistetter K, Krüger U, Schaefer H, Klosa J (1979) 4,4-Diphenylpiperidine — ein neuer Substanztyp für die Therapie des Morbus Parkinson. Österr Chemie 4:61
Menge HG, Brand U (1982) Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4-Diphenylpiperidin-Derivat für die Parkinson-Therapie. Arzneimittelforsch 32: 85
Siegfried J, Fischer R (1983) La place pour une nouvelle substance chimique dans le traitement de la maladie de Parkinson et le rôle de la Budipine. Médecine et Hygiène 41: 1977–1981
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Zech, K., Sturm, E., Ludwig, G. (1985). Pharmacokinetics and Metabolism of Budipine in Animals and Humans. In: Gerstenbrand, F., Poewe, W., Stern, G. (eds) Clinical Experiences with Budipine in Parkinson Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-95455-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-95455-9_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-13764-1
Online ISBN: 978-3-642-95455-9
eBook Packages: Springer Book Archive